Company / Cash & Equivalents
Denali Therapeutics Inc. Cash & Equivalents History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$205.3M
FY2025
5-year range
$127.1M / $293.5M
FY2021-FY2025
Trend
+17.4%
vs FY2024
Sector context
#84 of 207
Health Care
What the data says
At $205M, Denali Therapeutics Inc.'s cash & equivalents ranks #84 of 207 in the Health Care sector. Cash & Equivalents has fluctuated over the past 10 years, ranging from $40M in FY2016 to $507M in FY2020.
Based on SEC 10-K filings.
$205M in FY2025 with a 5-year CAGR of -16.5%.
Improved from $127M to $205M over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -2.0%
- 5-Year CAGR
- -16.5%
- 10-Year CAGR
- -
Sector benchmark
#84 of 207 in Health CareTop 41% of 207This company $205.3M Sector average $669.5M
▼
-69.3% below sector average
Key checks
Key Insights
- 5-year CAGR of -16.5%, indicating a declining trend.
- In FY2025, cash & equivalents increased 17.4% year-over-year.
- Ranks #84 out of 207 companies in the Health Care sector.
- Peak cash & equivalents was recorded in FY2020.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 0.73 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $205.3M | +17.4% |
| FY2024 | $175.0M | +37.6% |
| FY2023 | $127.1M | -41.7% |
| FY2022 | $218.0M | -25.7% |
| FY2021 | $293.5M | -42.1% |
| FY2020 | $507.1M | +557.6% |
| FY2019 | $77.1M | -64.7% |
| FY2018 | $218.4M | +0.0% |
| FY2017 | $218.4M | +448.0% |
| FY2016 | $39.9M | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026